BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 129, Issue 5, Pages 1878-1894
Publisher
American Society for Clinical Investigation
Online
2019-02-22
DOI
10.1172/jci120654
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
- (2017) D T Saenz et al. LEUKEMIA
- Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia
- (2016) S. Piya et al. BLOOD
- A 17-gene stemness score for rapid determination of risk in acute leukaemia
- (2016) Stanley W. K. Ng et al. NATURE
- ‘Acute myeloid leukemia: a comprehensive review and 2016 update’
- (2016) I De Kouchkovsky et al. Blood Cancer Journal
- A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia
- (2016) Konstantinos Tzelepis et al. Cell Reports
- Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang
- (2016) Hong-Sheng Zhou et al. Cancer Biology & Medicine
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
- (2015) Michael Zengerle et al. ACS Chemical Biology
- Amino Acid Transporters in Cancer and Their Relevance to "Glutamine Addiction": Novel Targets for the Design of a New Class of Anticancer Drugs
- (2015) Y. D. Bhutia et al. CANCER RESEARCH
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells
- (2015) Lina Han et al. CYTOMETRY PART A
- BET inhibitor resistance emerges from leukaemia stem cells
- (2015) Chun Yew Fong et al. NATURE
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Advances in understanding the leukaemia microenvironment
- (2014) Yoko Tabe et al. BRITISH JOURNAL OF HAEMATOLOGY
- Affinity Map of Bromodomain Protein 4 (BRD4) Interactions with the Histone H4 Tail and the Small Molecule Inhibitor JQ1
- (2014) Marie Jung et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents
- (2014) Bing Z. Carter et al. JNCI-Journal of the National Cancer Institute
- Targeted metabolomic analysis of amino acid response to L-asparaginase in adherent cells
- (2014) Preeti Purwaha et al. Metabolomics
- BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
- (2014) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- Metabolic requirements for the maintenance of self-renewing stem cells
- (2014) Keisuke Ito et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
- (2014) Jessica E. Bolden et al. Cell Reports
- Measurement of DNA Concentration as a Normalization Strategy for Metabolomic Data from Adherent Cell Lines
- (2013) Leslie P. Silva et al. ANALYTICAL CHEMISTRY
- Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment
- (2013) V. L. Battula et al. BLOOD
- BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
- (2013) Eleni D. Lagadinou et al. Cell Stem Cell
- CXC Chemokine Receptor 4 Expression, CXC Chemokine Receptor 4 Activation, and Wild-Type Nucleophosmin Are Independently Associated With Unfavorable Prognosis in Patients With Acute Myeloid Leukemia
- (2013) Sergej Konoplev et al. Clinical Lymphoma Myeloma & Leukemia
- Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition
- (2013) C. Chen et al. GENES & DEVELOPMENT
- Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation
- (2013) J. Shi et al. GENES & DEVELOPMENT
- CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia
- (2013) Ye Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization and is a marker for poor prognosis in acute myeloid leukemia
- (2013) L Brault et al. LEUKEMIA
- Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications
- (2013) C C Bjorklund et al. LEUKEMIA
- Modulation of oxidative stress as an anticancer strategy
- (2013) Chiara Gorrini et al. NATURE REVIEWS DRUG DISCOVERY
- Redox regulation in stem-like cancer cells by CD44 variant isoforms
- (2013) O Nagano et al. ONCOGENE
- A review on CXCR4/CXCL12 axis in oncology: No place to hide
- (2012) Urszula M. Domanska et al. EUROPEAN JOURNAL OF CANCER
- Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia
- (2012) Wan Zhang et al. NATURE CELL BIOLOGY
- Targeting Epigenetic Readers in Cancer
- (2012) Mark A. Dawson et al. NEW ENGLAND JOURNAL OF MEDICINE
- c-Myc is crucial for the expression of LAT1 in MIA Paca-2 human pancreatic cancer cells
- (2012) KEITARO HAYASHI et al. ONCOLOGY REPORTS
- CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc− and Thereby Promotes Tumor Growth
- (2011) Takatsugu Ishimoto et al. CANCER CELL
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts
- (2011) Y Tabe et al. LEUKEMIA
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Site-specific Phosphorylation of CXCR4 Is Dynamically Regulated by Multiple Kinases and Results in Differential Modulation of CXCR4 Signaling
- (2010) John M. Busillo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- High levels of the adhesion molecule CD44 on leukemic cells generate acute myeloid leukemia relapse after withdrawal of the initial transforming event
- (2010) R Quéré et al. LEUKEMIA
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Dissection of PIM serine/threonine kinases in FLT3-ITD–induced leukemogenesis reveals PIM1 as regulator of CXCL12–CXCR4-mediated homing and migration
- (2009) Rebekka Grundler et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
- (2008) Z. Zeng et al. BLOOD
- Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100
- (2008) B. Nervi et al. BLOOD
- Apoptotic signaling by c-MYC
- (2008) B Hoffman et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More